The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Age 18 \~ 75 years old, regardless of gender
* Patients with colorectal cancer diagnosed by histopathology or cytology
* Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy
* Having at least one assessable tumor focus
* ECoG physical condition score ≤ 2 points
* Voluntarily participate and sign informed consent
Exclusion Criteria:
* Patients diagnosed with metastasis
* Patients who cannot obtain tumor samples
* Pregnant and lactating women
* Patients with poor compliance
* Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment
* Patients with other malignant tumors
* Suffering from serious mental and nervous system diseases
* The researchers believe that patients should not be selected for this study
Primary outcome measure(s)
The difference of 3-year disease-free survival rate of patients in both group — 3 years Follow-up the survival status of patients, and calculate 3-year disease-free survival rate of patients in both group
Trial sites (1)
Facility
City
Region
Status
Peking Union Medical College Hospital
Beijing
Beijing Municipality
Recruiting
More Peking Union Medical College Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.